# Wockhardt (WOCKPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/wockpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,952.6
- Change: -1.86%
- As of: 2026-11-06
- 1D return: -1.86%
- 5D return: +2.71%
- 1M return: -3.79%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

WOCKPHARMA (₹1,952.60) is navigating a complex technical environment characterized by conflicting timeframes and elevated volatility. On the daily chart, price action is trapped between short-term support and immediate resistance, with the stock trading above its 20-period EMA and SMA but below the 50-period averages and a bearish Supertrend. This structure suggests a lack of clear directional conviction on the daily horizon, reinforced by a developing ADX of 21.51. Conversely, the weekly trend remains established and bullish (ADX 33.87), while the monthly trend shows an established directional bias despite a bearish Supertrend signal.

Participation spiked recently, with an extreme volume-price move on November 5 (+4.8% return, 2.66x volume ratio) following a sharp decline on November 3. The stock currently sits in the upper-middle portion of its 20-day (+61.8%) and 252-day (+64.8%) ranges, indicating relative strength over the long term but proximity to near-term overhead supply. Immediate resistance lies at ₹1,959.58 (0.36% above), followed by ₹1,972.90 (1.04% above). Support is found at ₹1,913.80 (1.99% below) and ₹1,901.00 (2.64% below). With annualized volatility at +53.1% and a current drawdown of -16.2%, risk management is critical. A daily close above ₹1,972.90 would be required to confirm a resumption of upward momentum, while a break below ₹1,913.80 would invalidate the short-term consolidation structure.

- Timeframe Conflict: Daily trend is indecisive (price below 50-period MA/Supertrend), while weekly trend remains bullish (ADX 33.87) and monthly trend shows established direction.
- Key Levels: Immediate resistance at ₹1,959.58 and ₹1,972.90; primary support zones at ₹1,913.80 and ₹1,901.00.
- Momentum & Participation: Extreme volume spike (+2.66x) accompanied a +4.8% gain on Nov 5, suggesting active institutional or large-cap participation after a prior drop.
- Risk Profile: High volatility (+53.1% annualized) and significant recent drawdown (-16.2%) require wide stop-loss buffers; position is in the upper-middle of the 252-day range.

- Inside Bar
- Outside Bar
- Bearish Engulfing Reversal
- Harami
- Morning Star

### News Context

Wockhardt reported its Q2 FY27 results on November 2, 2026, revealing a divergence between top-line growth and profitability. Consolidated revenue rose 24% year-on-year to ₹969 crore, driven primarily by the biotechnology segment, which saw revenue surge 68% to ₹252 crore. The company also expanded marketing access for its novel antibiotic Miqnaf in India after regulatory conditions were lifted and secured US FDA approval for Zaynich for complicated urinary tract infections.

Despite these operational gains, profit after tax declined 11% to ₹73 crore from ₹82 crore in the corresponding period last year. Media reports attribute this margin contraction specifically to expenses associated with the launch of Zaynich. While the biotech expansion and new product approvals signal positive business momentum, the immediate financial impact reflects the cost of commercializing new assets.

- Q2 FY27 consolidated revenue increased 24% YoY to ₹969 crore, supported by a 68% rise in biotech segment revenue to ₹252 crore.
- Profit after tax fell 11% to ₹73 crore (from ₹82 crore), with third-party reporting citing launch expenses for Zaynich as the primary driver of margin pressure.
- Operational developments include expanded marketing access for novel antibiotic Miqnaf in India following regulatory clearance and US FDA approval for Zaynich.

- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms)
- [Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins](https://www.moneycontrol.com/news/business/wockhardt-q2-net-profit-falls-11-as-zaynich-launch-expenses-weigh-on-margins-14066581.html)
- [Q2 Results Today Live: ITC, Marico, UPL, Petronet LNG, NLC, DOMS, Escorts Kubota, NALCO, MobiKwik, Wockhardt, Granules to announce Q2 results, Reliance, Jio Platforms, NTPC shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)

### Official Filings

Wockhardt Limited’s Board approved unaudited financial results for the quarter and half-year ended September 30, 2026, on November 2, 2026. Consolidated net profit after tax stood at ₹82 crore for the quarter and ₹180 crore for the six-month period, though these figures include an exceptional charge of ₹97 crore. Standalone revenue grew 24% year-on-year to ₹969 crore in Q2 FY27. Biotech operations saw significant momentum, with H1 FY27 revenue reaching ₹487 crore, reflecting 87% growth driven by emerging markets. The company also highlighted regulatory milestones, noting that five novel antibiotics completed Phase 3 trials, with Zaynich receiving US FDA approval for cUTI/pyelonephritis and CDSCO approval in India. Concurrently, the Board designated Sumit Garg as Chief Digital & Information Officer and Senior Management Personnel effective November 2, 2026. Additionally, 20,000 equity shares were allotted on October 27, 2026, under the Employee Stock Option Scheme-2011, increasing the paid-up capital to ₹81,25,60,845.

- Consolidated net profit was ₹82 crore (Q2) and ₹180 crore (H1), inclusive of a ₹97 crore exceptional charge; standalone revenue rose 24% YoY to ₹969 crore.
- Biotech segment revenue reached ₹487 crore in H1 FY27, marking 87% growth, while Zaynich secured US FDA and CDSCO approvals following Phase 3 completion.
- Sumit Garg appointed as Chief Digital & Information Officer and designated Senior Management Personnel effective November 2, 2026.
- Share capital increased to ₹81,25,60,845 via allotment of 20,000 ESOP shares on October 27, 2026.

- [Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2026; |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026161333_BMOutcome02112026signed.pdf)
- [Wockhardt Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026165707_PressReleasesigned.pdf)
- [WOCKHARDT LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1863_WebXMLFile_20261102_171208607.xml)
- [In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e. 2nd November, 2026, inter-alia, has identified and designated Mr. Sumit Garg, Chief Digital & Information Officer as Senior Management Personnel (SMP) of the Company. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026171023_changeinmanagementMrSumitGargs.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751350_02112026065436_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751379_02112026071126_WEB.xml)
- [Financial Results |Meeting Date: 02-Nov-2026](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_27102026110726_BMIntimation02112026sd.pdf)
- [Board Meeting Intimation |Meeting Date: 02-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1863_WebXMLFile_20261027_111900360.xml)
- [WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1863_WebXMLFile_20261027_111900360.xml)
- [We wish to inform you that the Share Allotment Committee of the Board of Directors of the Company has allotted 20,000 equity shares of face value of Rs.5/- each on 27th October, 2026, pursuant to exercise of stock options under Employee Stock Options Scheme - 2011 of the Company. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_27102026123738_WLintimationESOP271026Sd_final.pdf)

### Fundamentals

Wockhardt’s operating trajectory has strengthened significantly, with TTM sales rising to ₹3,751 crore and TTM net profit surging to ₹405 crore. This follows a strong annual recovery in FY2026, where net profit turned positive at ₹199 crore against a loss of ₹57 crore in FY2025. However, recent quarterly momentum shows signs of deceleration; Q2 FY2026-27 revenue (₹580 crore) grew sequentially from Q1 (₹561 crore), but both sequential revenue and net profit declined compared to the prior year's September quarter (Sales: ₹969 crore; Net Profit: ₹73 crore). Earnings quality remains a key area to monitor, as the Cash Conversion Cycle deteriorated sharply from 41 days in Mar 2024 to 168 days in Mar 2026, driven by Inventory Days increasing to 286 days. Despite this, the balance sheet is stabilizing: borrowings rose modestly to ₹2,238 crore in Sep 2026, while cash reserves nearly doubled to ₹148 crore. Fixed assets expanded substantially to ₹4,655 crore, reflecting ongoing capital expenditure, while CWIP dropped significantly to ₹676 crore, suggesting asset completion.

Key Points:
- **Profitability Recovery:** TTM net profit jumped to ₹405 crore, reversing the ₹57 crore loss in FY2025, though Q2 FY2026-27 sequential profits declined to ₹100 crore.
- **Working Capital Pressure:** The Cash Conversion Cycle widened to 168 days (Mar 2026) due to inventory buildup (286 days), offsetting faster debtor collections (64 days).
- **Balance Sheet Expansion:** Total assets grew to ₹6,180 crore (Sep 2026) with fixed assets rising to ₹4,655 crore, while cash holdings increased to ₹148 crore.
- **Next Checkpoint:** Monitor whether Q3 FY2026-27 results show stabilization in working capital cycles and if sequential revenue growth resumes after the Q2 decline.

### Bull Case

Wockhardt’s Q2 FY27 results highlight a structural shift in revenue generation, with the biotechnology segment driving a 68% year-on-year increase to ₹252 crore. This growth contributed to a 24% rise in consolidated revenue to ₹969 crore, underscoring the expanding commercial relevance of its novel antibiotic Miqnaf following lifted regulatory conditions and the US FDA approval for Zaynich. While near-term profitability was impacted by launch expenses—resulting in an 11% decline in net profit to ₹73 crore—the top-line momentum in high-growth segments provides a constructive foundation. Technically, the stock is trading at ₹1,952.60 on November 6, 2026, with a market capitalization of approximately ₹32,331 crore. Although daily and monthly trends are bearish, the weekly trend remains bullish, suggesting that medium-term price stability could be supported if operational execution continues to offset one-time launch costs.

- Biotech revenue surged 68% to ₹252 crore in Q2 FY27, contributing significantly to a 24% overall revenue increase to ₹969 crore.
- Consolidated net profit declined 11% to ₹73 crore due to specific launch expenses for Zaynich, creating a temporary margin headwind.
- Weekly technical trend remains bullish despite bearish daily and monthly signals, with the stock trading at ₹1,952.60 as of November 6, 2026.
- Regulatory progress includes expanded access for Miqnaf in India and US FDA approval for Zaynich for complicated urinary tract infections.

- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms)
- [Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins](https://www.moneycontrol.com/news/business/wockhardt-q2-net-profit-falls-11-as-zaynich-launch-expenses-weigh-on-margins-14066581.html)
- [Q2 Results Today Live: ITC, Marico, UPL, Petronet LNG, NLC, DOMS, Escorts Kubota, NALCO, MobiKwik, Wockhardt, Granules to announce Q2 results, Reliance, Jio Platforms, NTPC shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2026; |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026161333_BMOutcome02112026signed.pdf)
- [Wockhardt Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026165707_PressReleasesigned.pdf)
- [WOCKHARDT LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1863_WebXMLFile_20261102_171208607.xml)
- [In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e. 2nd November, 2026, inter-alia, has identified and designated Mr. Sumit Garg, Chief Digital & Information Officer as Senior Management Personnel (SMP) of the Company. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026171023_changeinmanagementMrSumitGargs.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751350_02112026065436_WEB.xml)

### Bear Case

Wockhardt’s Q2 FY27 results highlight a divergence between top-line growth and bottom-line profitability, signaling operational margin pressure. Consolidated revenue rose 24% to ₹969 crore, driven by a 68% surge in the biotechnology segment to ₹252 crore and expanded access for the novel antibiotic Miqnaf. However, profit after tax contracted 11% to ₹73 crore from ₹82 crore in the prior-year period. This decline is attributed to launch expenses for Zaynich, which weighed on margins despite regulatory approvals for the drug in the US for complicated urinary tract infections. The market has priced in this volatility, with the stock trading at ₹1,952.60 as of November 6, 2026, reflecting a significant 16.2% current drawdown from recent highs. Technical indicators show bearish momentum on daily and monthly timeframes, with the Supertrend direction negative, suggesting near-term selling pressure may persist despite longer-term weekly bullishness.

- Profitability contraction: Net profit fell 11% to ₹73 crore in Q2 FY27 despite a 24% revenue increase to ₹969 crore, due to launch costs for Zaynich.
- Margin pressure: Biotech revenue grew 68% to ₹252 crore, but overall margins declined as specific product launch expenses impacted the bottom line.
- Technical weakness: Daily and monthly Supertrend directions are bearish; the stock is down 16.2% from its peak, with resistance near ₹1,959.58.
- Volatility risk: Annualized volatility stands at 53.1%, indicating high price fluctuation and potential downside deviation of 27.2%.

- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms)
- [Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins](https://www.moneycontrol.com/news/business/wockhardt-q2-net-profit-falls-11-as-zaynich-launch-expenses-weigh-on-margins-14066581.html)
- [Q2 Results Today Live: ITC, Marico, UPL, Petronet LNG, NLC, DOMS, Escorts Kubota, NALCO, MobiKwik, Wockhardt, Granules to announce Q2 results, Reliance, Jio Platforms, NTPC shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2026; |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026161333_BMOutcome02112026signed.pdf)
- [Wockhardt Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026165707_PressReleasesigned.pdf)
- [WOCKHARDT LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1863_WebXMLFile_20261102_171208607.xml)
- [In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e. 2nd November, 2026, inter-alia, has identified and designated Mr. Sumit Garg, Chief Digital & Information Officer as Senior Management Personnel (SMP) of the Company. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026171023_changeinmanagementMrSumitGargs.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751350_02112026065436_WEB.xml)

### FAQs

**How did Wockhardt's Q2 FY27 financial results perform, and what drove the changes?**

For the quarter ended September 30, 2026, Wockhardt reported a 24% year-on-year revenue increase to ₹969 crore, driven by an 87% growth in its biotech segment. However, Profit After Tax (PAT) declined 11% to ₹73 crore due to launch expenses for Zaynich and an exceptional charge of ₹97 crore.

**What are the key operational milestones highlighted in the recent results?**

The company expanded marketing access for novel antibiotic Miqnaf in India after regulatory conditions were lifted. Additionally, Zaynich received US FDA approval for complicated urinary tract infections and CDSCO approval for manufacturing and marketing in India. Five novel antibiotics completed Phase 3 trials.

**What is the current technical price structure for Wockhardt shares on NSE?**

As of November 6, 2026, the stock closed at ₹1,952.60 with a market cap of approximately ₹32,331 crore. The daily trend is bearish, with immediate resistance at ₹1,959.58 and support at ₹1,913.80. The stock has returned +44.3% over the past year but is currently in a -16.2% drawdown from its peak.

- [Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- [Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms)
- [Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins](https://www.moneycontrol.com/news/business/wockhardt-q2-net-profit-falls-11-as-zaynich-launch-expenses-weigh-on-margins-14066581.html)
- [Q2 Results Today Live: ITC, Marico, UPL, Petronet LNG, NLC, DOMS, Escorts Kubota, NALCO, MobiKwik, Wockhardt, Granules to announce Q2 results, Reliance, Jio Platforms, NTPC shares in focus](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- [Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2026; |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026161333_BMOutcome02112026signed.pdf)
- [Wockhardt Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026165707_PressReleasesigned.pdf)
- [WOCKHARDT LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1863_WebXMLFile_20261102_171208607.xml)
- [In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e. 2nd November, 2026, inter-alia, has identified and designated Mr. Sumit Garg, Chief Digital & Information Officer as Senior Management Personnel (SMP) of the Company. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026171023_changeinmanagementMrSumitGargs.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751350_02112026065436_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹1,972.9
- Risk regime: Price Risk Requires Attention

### Support levels
- 1901
- 1818.625
- 1645.2

### Resistance levels
- 1959.575
- 2053.65
- 2120

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -1.86% |
| return_10 | +8.38% |
| return_1m | -10.28% |
| return_1y | +44.28% |
| return_20 | -3.79% |
| return_3m | -1.13% |
| return_5 | +2.71% |
| return_6m | +13.73% |
| return_since_start | +34.13% |
| return_ytd | +37.23% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -39.91% |
| annualized_volatility | +53.14% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Wockhardt Limited FY2026-27 Q2: Revenue reaches ₹580 crore

Standalone revenue rose 3.4% quarter on quarter to ₹580 crore, while profit before exceptional items and tax and profit for the period each fell 6.5% to ₹100 crore. Year on year, revenue increased 52.6% and both profit measures rose 85.2%, to more than the prior-year quarter’s ₹54 crore.

## Revenue and expenses

Revenue has risen for four consecutive quarters, from ₹430 crore in Q3 FY2025-26 to ₹516 crore in Q4 FY2025-26, ₹561 crore in Q1 FY2026-27 and ₹580 crore in Q2 FY2026-27. Expenses increased 2.9% quarter on quarter to ₹501 crore from ₹487 crore. Year on year, expenses rose 40.7% to ₹501 crore from ₹356 crore, below revenue growth of 52.6% over the same period.

## Profit and finance costs

Profit before exceptional items and tax and profit for the period were each ₹100 crore in Q2 FY2026-27, down from ₹107 crore in Q1 FY2026-27. Compared with Q2 FY2025-26, both were up from ₹54 crore. Finance costs rose 11.6% quarter on quarter to ₹48 crore from ₹43 crore, and were ₹44 crore in Q2 FY2025-26.

In Q4 FY2025-26, profit before exceptional items and tax was ₹132 crore and profit for the period was ₹167 crore. In Q3 FY2025-26, the respective figures were ₹38 crore and ₹28 crore.

## Balance sheet

At 30 September 2026, total assets were ₹6,180 crore, compared with ₹5,935 crore at 31 March 2026 and ₹5,942 crore at 30 September 2025. Equity stood at ₹3,293 crore, up from ₹3,084 crore and ₹2,886 crore at those dates, respectively. Total liabilities were ₹2,887 crore, versus ₹2,851 crore at 31 March 2026 and ₹3,056 crore a year earlier.

Total borrowings were ₹1,804 crore at 30 September 2026, comprising ₹627 crore of current and ₹1,177 crore of noncurrent borrowings. This compared with ₹1,745 crore at 31 March 2026 and ₹1,963 crore at 30 September 2025. Cash and cash equivalents were ₹148 crore, up from ₹76 crore at 31 March 2026 and ₹59 crore a year earlier.

Trade receivables increased to ₹961 crore at 30 September 2026 from ₹731 crore a year earlier, while inventories rose to ₹596 crore from ₹501 crore.

## Key Takeaway

Revenue and profit were substantially higher year on year, but both profit measures eased from Q1 FY2026-27 as finance costs also increased. Equity and cash balances were above their year-ago levels, while total borrowings were lower year on year but higher than at 31 March 2026.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +49.08%
- FII holding: +7.22%
- DII holding: +9.24%
- Mutual fund holding: +6.79%
- Retail holding: +19.47%
- Promoter pledged: +0.00%

### Major reported shareholders

- Themisto Trustee Company Private Limited — +40.15% (Partnership Firms)
- Pasithee Trustee Company Private Limited — +2.72% (Partnership Firms)
- Ananke Trustee Company Private Limited — +2.35% (Partnership Firms)
- Tata Mutual Fund - Tata Small Cap Fund — +2.03%
- Callirhoe Trustee Company Private Limited — +1.92% (Partnership Firms)
- Rekha Jhunjhunwala — +1.75%
- Hsbc Mutual Fund - Hsbc Small Cap Fund — +1.30%
- 3p India Equity Fund 1 — +1.15%
- Callirhoe Trustee Company Private Limited — +0.58% (Trusts)
- Pasithee Trustee Company Private Limited — +0.40% (Trusts)

## Official filings

- 2026-11-02 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026161333_BMOutcome02112026signed.pdf)
- 2026-11-02 — Press Release: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026165707_PressReleasesigned.pdf)
- 2026-11-02 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1863_WebXMLFile_20261102_171208607.xml)
- 2026-11-02 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_02112026171023_changeinmanagementMrSumitGargs.pdf)
- 2026-11-02 — Financial Results Filing: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751350_02112026065436_WEB.xml)
- 2026-11-02 — Financial Results Filing: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751379_02112026071126_WEB.xml)
- 2026-10-27 — Board Meeting Notice: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_27102026110726_BMIntimation02112026sd.pdf)
- 2026-10-27 — Board Meeting Notice: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1863_WebXMLFile_20261027_111900360.xml)
- 2026-10-27 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1863_WebXMLFile_20261027_111900360.xml)
- 2026-10-27 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_27102026123738_WLintimationESOP271026Sd_final.pdf)
- 2026-10-27 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_1863_WebXMLFile_20261027_124802548.xml)
- 2026-10-24 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_24102026125756_Relodgementoftransfernoticesigned.pdf)
- 2026-10-19 — Shareholding Disclosure: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1741805_19102026055732_WEB.xml)
- 2026-10-09 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_09102026143603_Regulation74_5_certificate.pdf)
- 2026-09-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_25092026125542_Trading_Window_Closuresigned.pdf)
- 2026-09-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_1863_WebXMLFile_20260925_125750571.xml)
- 2026-08-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_25082026164336_Relodgementoftransfernoticesigned.pdf)
- 2026-08-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_1863_WebXMLFile_20260825_185530371.xml)
- 2026-08-10 — Management Change: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026193556_AGMfilingCombinedsigned.pdf)
- 2026-08-10 — Press Release: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026164749_CombinePressPresssigned.pdf)
- 2026-08-10 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026151949_OutcomeBM10082026dsigned.pdf)
- 2026-08-10 — Credit Rating Update: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026183757_Combine_MA_Report_Signed.pdf)
- 2026-08-07 — Generic Announcement: Wockhardt Limited has published an addendum to the notice of its 27th Annual General Meeting in Business Standard and Lokmat newspapers on August 7, 2026. The company will also place these newspaper extracts on its website. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_07082026152835_newspaperintimation2026.pdf)
- 2026-08-05 — Official Filing: Wockhardt Limited revised the time of its 27th Annual General Meeting (AGM) from 3:30 p.m. to 10:30 a.m. IST on August 10, 2026, to be held via VC/OAVM. The company also reported related party transactions totaling INR 16,500,000,000 across various domains, including intellectual property and goods/services with subsidiaries Wockhardt Bio AG, CP Pharmaceuticals Limited, and Wockhardt UK Limited. Resolutions approved include the adoption of financial statements, re-appointment of Ms. Zahabiya Khorakiwala, ratification of cost auditor remuneration, revision of Dr. Habil Khorakiwala's remuneration to INR 150,000,000, and approval for raising up to INR 3,000 Crore via QIP.
- 2026-08-05 — Generic Announcement: Wockhardt Limited issued an addendum to the notice of its 27th Annual General Meeting (AGM), scheduled for August 10, 2026. The AGM's start time has been revised from 3:30 p.m. IST to 10:30 a.m. IST. The addendum also includes a statement regarding information provided to the Audit Committee for related party transactions, confirming that the Managing Director and CFO certified these transactions are in the company's interest. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_05082026205000_AddendumtoNoticeSEFinal.pdf)

## News and market events

- 2026-11-03 — CNBC-TV18: **Here are five Pharma and Healthcare stocks that will be reacting to their Q2 results today** — Five pharmaceutical and healthcare stocks—Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs—are reacting to their September quarter results reported after market hours on Monday. Granules India reported steady revenue growth but faced margin softening due to slowing US formulations business, while Wockhardt saw a 24% revenue increase driven by biotech operations despite margin contraction. Other companies showed varied performance, with Akums Drugs doubling net profit and Krsnaa Diagnostics increasing revenue by 31.5%, whereas SPARC's subsidiary narrowed its losses. — [Source](https://www.cnbctv18.com/market/granules-india-wockhardt-sparc-krsnaa-diagnostics-akums-drugs-share-price-q2-results-20025420.htm)
- 2026-11-02 — Economic Times: **Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%** — Wockhardt expanded marketing access for its novel antibiotic Miqnaf in India after regulatory conditions were lifted, contributing to a 24% year-on-year rise in consolidated revenue to Rs 969 crore in the second quarter of FY27. The company also highlighted US FDA approval for Zaynich for complicated urinary tract infections and reported significant growth in its biotechnology segment, which saw revenue increase by 68% to Rs 252 crore. Despite these top-line gains, Wockhardt's profit after tax declined slightly to Rs 73 crore from Rs 82 crore in the corresponding period last year. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/wockhardt-expands-novel-antibiotic-miqnafs-access-q2-revenue-rises-24/articleshow/135460959.cms)
- 2026-11-02 — MONEYCONTROL: **Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins** — Wockhardt reported an 11% decline in its Q2 net profit, driven by expenses associated with the launch of Zaynich that weighed on margins. The financial result reflects the impact of these specific launch costs on the company's profitability for the quarter. — [Source](https://www.moneycontrol.com/news/business/wockhardt-q2-net-profit-falls-11-as-zaynich-launch-expenses-weigh-on-margins-14066581.html)
- 2026-11-02 — The Hindu: **Q2 Results Today Live: ITC, Marico, UPL, Petronet LNG, NLC, DOMS, Escorts Kubota, NALCO, MobiKwik, Wockhardt, Granules to announce Q2 results, Reliance, Jio Platforms, NTPC shares in focus** — Multiple listed Indian companies including ITC, Marico, UPL, Petronet LNG, NLC India, DOMS Industries, Escorts Kubota, National Aluminium Company, One Mobikwik Systems, and Wockhardt are scheduled to announce their Q2 fiscal year 2026 financial results on November 2, 2026. Shares of Reliance, Jio Platforms, and NTPC are also noted as being in focus during this period. — [Source](https://www.thehindubusinessline.com/markets/q2-results-today-live-updates-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- 2026-11-02 — The Hindu: **Q2 Results Today Highlights: Marico, Petronet LNG & Granules Q2 profit surges, ITC, UPL , Wockhardt & Escorts Kubota PAT down, MobiKwik posts profit, Devyani International loss narrows** — Several listed companies reported their Q2FY27 standalone financial results, with Petronet LNG and Marico showing significant profit growth, while Escorts Kubota saw a decline in profit after tax. — [Source](https://www.thehindubusinessline.com/markets/q2-results-today-highlights-itc-marico-upl-upl-petronet-lng-nlc-india-mobikwik-wockhardt-nalco-doms-ind-bosch-escorts-kubota-granules-lloyds-ril-jio-company-results-02-november-2026/article71652562.ece)
- 2026-09-27 — MONEYCONTROL: **Broader markets underperform, extend losing streak to third week** — Midcap,Smallcap,Broader indices,Market this week,midcap this week,smallcap this week — [Source](https://www.moneycontrol.com/news/business/markets/broader-markets-underperform-extend-losing-streak-to-third-week-14039106.html)
- 2026-09-21 — MONEYCONTROL: **Pharma stocks rise up to 6% amid defensive buying, strong product pipeline; Mankind Pharma, Wockhardt lead gains** — Pharma stocks, Sun Pharma — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-rise-up-to-6-amid-defensive-buying-strong-product-pipeline-mankind-pharma-wockhardt-lead-gains-14034517.html)
- 2026-09-17 — The Hindu: **Biotechnology and healthcare: where we are in India, and where we need to go** — Explore India's biotechnology landscape and its potential to revolutionize healthcare, enhancing access, innovation, and economic growth for the future. — [Source](https://www.thehindu.com/sci-tech/health/biotechnology-and-healthcare-where-we-are-in-india-and-where-we-need-to-go/article71471597.ece)
- 2026-09-09 — Economic Times: **French food giant Danone eyes India growth without 'burning its wings'** — Danone aims for India to be a significant long-term growth engine.CEO Antoine de Saint-Affrique emphasizes profitable expansion, avoiding rapid market entry.The company focuses on specialized nutrition, building its Aptamil brand's credibility.India's demographics and growing demand for premium baby-care products are key.Danone is intentionally investing to build a sizable business from a small base. — [Source](https://economictimes.indiatimes.com/industry/services/retail/french-food-giant-danone-eyes-india-growth-without-burning-its-wings/articleshow/133982342.cms)
- 2026-09-08 — BUSINESS: **Wockhardt Ltd up for five straight sessions** — Wockhardt Ltd is quoting at Rs 2214, up 0.27% on the day as on 12:44 IST on the NSE. The stock is up 48.22% in last one year as compared to a 4.86% gain in NIFTY and a 21.83% gain in the Nifty Pharma. — [Source](https://www.business-standard.com/markets/capital-market-news/wockhardt-ltd-up-for-five-straight-sessions-126090800533_1.html)
- 2026-09-07 — CNBC-TV18: **Wockhardt shares rise 7%, extend gains for fourth consecutive session** — The Wockhardt stock has gained for seven of the previous 10 trading sessions. The company's shares were also the biggest gainer on the Nifty Pharma index in intraday trade on Monday. — [Source](https://www.cnbctv18.com/market/wockhardt-share-price-rise-fourth-straight-session-gain-top-nifty-pharma-gainer-19985466.htm)
- 2026-09-07 — Economic Times: **Wockhardt Share Price Today, Wockhardt Stock Price Live NSE/BSE Updates | The Economic Times** — Wockhardt Share Price Today - Get live NSE/BSE quotes of Wockhardt with latest news, headlines and quick analysis. View forecasts, quarterly results, dividend details, balance sheet & more. — [Source](https://economictimes.indiatimes.com/wockhardt-ltd/stocks/companyid-3731.cms)
- 2026-09-07 — MONEYCONTROL: **Trade Spotlight: How should you trade IFCI, Balaji Amines, ACME Solar Holdings, Indraprastha Gas, Tata Communications, and others on September 7?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-ifci-balaji-amines-acme-solar-holdings-indraprastha-gas-tata-communications-and-others-on-september-7-14023879.html)
- 2026-09-06 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Monday** — Indian benchmark indices ended slightly higher on Friday, with the Sensex rising 363 points and Nifty closing below 23,898. Investors monitored global market cues, US economic data, and inflation reports, while stock-specific action drove intraday activity across major sectors in a sideways-moving market environment. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-monday/articleshow/133834844.cms)
- 2026-08-11 — The Hindu: **Q1 Results Today Live:  Siemens, Zydus Lifesciences, MRF, RVNL, PI Industries, Manappuram Finance, NBCC, Kalpataru, Swan Defence, Bata, Gujarat Energy, KPI Green to announce Q1 results, Vi, Bosch, Zee, Bharat Forge, Hindustan Copper, Info Edge in focus** — Q1 Results Today, 11th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-siemens-zydus-lifescience-mrf-rvnl-pi-industries-manappuram-finance-nbcc-kalpataru-swan-defence-bata-gujarat-energy-kpi-green-vi-bosch-zee-results-11-august-2026/article71327946.ece)
- 2026-08-10 — Economic Times: **Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore** — 2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/independence-day-2026-india-pharma-journey-covaxin-made-in-india-drug-discovery-zaynich-wockhardt-ipa-indian-medicine-vaccine/articleshow/133003617.cms)
- 2026-08-10 — MONEYCONTROL: **Wockhardt Ltd posts Q1 PAT of Rs 107 crore** — Wockhardt Q1 results, Wockhardt q1 net profit — [Source](https://www.moneycontrol.com/news/business/earnings/wockhardt-ltd-posts-q1-pat-of-rs-107-crore-14000558.html)
- 2026-08-10 — CNBC-TV18: **Wockhardt swings to ₹106 crore profit in Q1 on 26% revenue growth** — Shares of Wockhardt Ltd ended at ₹1,932.60, down by ₹88.10, or 4.36%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/wockhardt-share-price-swings-to-rs-106-crore-profit-in-q1-on-26-revenue-growth-19965713.htm)
- 2026-08-10 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Bharat Forge extends losses to 8%; Nifty below 24,550** — Sensex Today | Stock Market LIVE Updates: We are at the halfway mark of the first day of trade, and the markets are trading in a volatile space, as the Nifty index remains cautious. The index is looking to hold onto the 24,500 mark. The Nifty Bank is also under pressure, down 100 points. SBI, Adani Ports and HDFC Life are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-banks-midcaps-bajaj-fin-pfc-kaynes-ola-bharat-forge-share-price-liveblog-19965161.htm)
- 2026-08-10 — CNBC-TV18: **Q1 Results LIVE Updates: Titan, Ola Electric react to earnings; Bharat Forge, Vodafone Idea report today** — Q1 Results LIVE Updates: Bharat Forge Vodafone Idea, Hindustan Copper, Wockhardt, Info Edge, Zee Entertainment, Linde India, ideaForge, Gland Pharma, Bosch, Astra Micro, AstraZeneca Pharma, are among the companies reporting their earnings today. Earnings reactions will come from stocks like Kaynes Tech, PFC, Delhivery and many other stocks. Watch this space for all the LIVE results updates of the first quarter. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-vodafone-idea-bharat-forge-pfc-kaynes-sbi-oil-titan-wockhardt-hind-copper-delhivery-ola-share-price-liveblog-19965183.htm)
- 2026-08-04 — MONEYCONTROL: **Trade Spotlight: How should you trade Wockhardt, Rail Vikas Nigam, Siemens, IndiGo, Grasim, Action Construction Equipment, and others on August 4?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Hindustan Zinc,Wockhardt,Rail Vikas Nigam,Siemens,InterGlobe Aviation,Grasim Industries,Whirlpool of India,Action Construction Equipment,Gland Pharma,Aether Industries — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-wockhardt-rail-vikas-nigam-siemens-indigo-grasim-action-construction-equipment-and-others-on-august-4-13992962.html)

## Business profile

**Strategic vision:** Pharmaceutical and biotechnology company focused on research and development.

### Business segments
- **India Branded Business:** This segment likely involves the sale of branded pharmaceutical products within the Indian market.
- **Active Pharmaceutical Ingredients (API):** Wockhardt produces and supplies Active Pharmaceutical Ingredients (APIs) to other pharmaceutical manufacturers.
- **Quality Generics:** The company offers quality generic pharmaceutical products catering to broader markets.
- **Biopharmaceuticals:** Wockhardt is involved in the production of biopharmaceutical products.
- **Nutrition Products:** The company offers a range of nutrition products.
- **Vaccines:** Wockhardt produces and sells vaccines.
- **Super Specialty Hospitals:** Wockhardt operates a chain of Super Specialty Hospitals, providing healthcare services.

### Competitive strengths
- Focus on research and development for unmet medical needs.
- Integrated business model spanning pharmaceutical manufacturing and healthcare services.
- Global distribution network across multiple key markets.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Gland Pharma Limited (Healthcare)](https://faxioms.com/stocks/gland) — +0.78%
- [IPCA Laboratories Limited (Healthcare)](https://faxioms.com/stocks/ipcalab) — -0.58%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/wockpharma
Markdown representation: https://faxioms.com/stocks/wockpharma?render=md